|
|
BioInformant, the first and only market research firm to specialize in the stem cell industry, announces the release of its “Global Cord Blood & Tissue Banking Industry Report – Market Size, Segmentation, & Forecasts, 2024.” This market report reveals key forces affecting the industry, presenting trend rate data for cord blood and tissue clinical trials, patents, grants, and scientific publications. It reveals public and private storage counts for cord blood and tissue on a global basis, as well as market size metrics for the public and private sectors, accompanied by future forecasts.
Over the past few years, the cord blood banking industry has substantially matured and consolidated, creating both threats and opportunities for the industry. Serious threats to the industry include low rates of utilization for stored cord blood, expensive cord blood transplantation procedures, difficulty educating obstetricians about cellular therapies, and an increasing trend toward industry consolidation.
However, there are also emerging opportunities for the industry, such as accelerated regulatory pathways for cell therapies in leading countries worldwide, including the U.S., Japan, South Korea, and EU. Cord blood banks are also diversifying into new types of stem cell storage, including cord tissue, placental tissue, amniotic tissue, menstrual fluid, adipose tissue, and more.
With the introduction of these new types of stem cell services, cord blood storage counts are becoming an outdated metric and “Revenue Generating Units” (RGUs) is becoming a more appropriate term.
Holding companies are also emerging as a global theme, allowing for increased operational efficiency and economy of scale. Cryoholdco has been acquiring cord blood banks throughout Latin America and Sanpower Group has been purchasing them within Asia.
Furthermore, growing investment is flowing into technologies to support ex vivo expansion of cord blood. Key strategies being explored for this purpose include nicotinamide-mediated (NAM) expansion, Notch ligand, SR-1, UM171, PGE2, and enforced fucosylation, among others. Market players developing cord blood expansion technologies include Nohla Therapeutics, ExcellThera, Gamida Cell Ltd, Novartis, Fate Therapeutics, Plasticell, and others.
Also, the term “cord blood” has become one of the 20 most expensive search terms on Google, a clear metric that indicates the competitiveness of the global market.
While market factors can vary by geography, it is crucial to have a global understanding of the market. Research advances, clinical trial findings, and technology advances do not know international boundaries. The cord blood market is global in nature and understanding dynamics limited to your region is not sufficient for making strategic, informed, and profitable decisions.
Based in Washington, DC, BioInformant has 18+ years of experience in tracking the cord blood banking industry, attends and chairs global conferences about cord blood and perinatal tissues, and is a thought-leader interviewed by media sources that include the Wall Street Journal, Xconomy, and Vogue Magazine. The report aggregates finding from decades of historical data, as well as dozens of interviews conducted with leading executives from across the stem cell and cord blood industry.
Tell Us What You Think!